Trial Site Detail
Drug: |
Imatinib + PKC412 |
|||
|---|---|---|---|---|
Trial: |
A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Completed |
|||
Robert Roessle Comprehensive Cancer Center - Charite Campus BuchLindenberger Weg 80 |
Principal Investigator: |
Peter Reichardt, MD |
|---|---|
Contact: |
49-304-5055-3893 reichardt@rrk-berlin.de |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Robert Roessle Comprehensive Cancer Center - Charite Campus Buch Website: |
http://cccc.charite.de/en/ |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.